A number of other research firms also recently issued reports on OCUL. ValuEngine upgraded shares of Ocular Therapeutix from a sell rating to a hold rating in a report on Tuesday, June 6th. Zacks Investment Research raised shares of Ocular Therapeutix from a hold rating to a buy rating and set a $11.00 target price for the company in a research note on Tuesday, May 16th. Cantor Fitzgerald reaffirmed an overweight rating and set a $35.00 price objective on shares of Ocular Therapeutix in a research report on Monday, May 15th. Finally, Morgan Stanley cut shares of Ocular Therapeutix from an overweight rating to an equal weight rating and set a $16.00 price objective for the company. in a research report on Friday, June 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Ocular Therapeutix presently has a consensus rating of Hold and an average target price of $22.14.
Shares of Ocular Therapeutix (NASDAQ:OCUL) traded up 2.94% during trading on Monday, hitting $5.95. 337,824 shares of the company were exchanged. The stock’s market cap is $172.88 million. Ocular Therapeutix has a 12 month low of $4.82 and a 12 month high of $11.91. The company’s 50-day moving average price is $7.24 and its 200 day moving average price is $8.63.
Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.05. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.51 million. Ocular Therapeutix had a negative return on equity of 101.03% and a negative net margin of 3,005.52%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.46) earnings per share. On average, equities analysts predict that Ocular Therapeutix will post ($2.21) earnings per share for the current fiscal year.
WARNING: This report was reported by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/14/ocular-therapeutix-inc-ocul-receives-neutral-rating-from-btig-research-updated-updated-updated.html.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. American International Group Inc. increased its position in Ocular Therapeutix by 8.2% in the first quarter. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 844 shares during the period. Highbridge Capital Management LLC bought a new position in Ocular Therapeutix during the first quarter worth approximately $107,000. Janney Montgomery Scott LLC bought a new position in Ocular Therapeutix during the first quarter worth approximately $110,000. Nationwide Fund Advisors increased its position in Ocular Therapeutix by 10.8% in the second quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,204 shares during the period. Finally, State of Wisconsin Investment Board acquired a new position in shares of Ocular Therapeutix during the second quarter valued at approximately $167,000. 65.04% of the stock is owned by institutional investors and hedge funds.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.